RC
TEVA icon

RegentAtlantic Capital’s Teva Pharmaceuticals TEVA Stock Holding History

RegentAtlantic Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$82K Hold
10,205
– – ﹤0.01% 655
2022
Q2 		$77K Hold
10,205
– – ﹤0.01% 664
2022
Q1 		$96K Hold
10,205
– – ﹤0.01% 676
2021
Q4 		$82K Sell
10,205
-2,000
-16% -$18.1K ﹤0.01% 677
2021
Q3 		$119K Buy
+12,205
New +$114K ﹤0.01% 647
2017
Q2 		– Sell
-7,083
Closed -$227K – 411
2017
Q1 		$227K Sell
7,083
-6,647
-48% -$227K 0.02% 373
2016
Q4 		$498K Sell
13,730
-9,205
-40% -$368K 0.05% 270
2016
Q3 		$1.05M Sell
22,935
-8,948
-28% -$467K 0.11% 183
2016
Q2 		$1.6M Sell
31,883
-7,153
-18% -$381K 0.15% 140
2016
Q1 		$289K Sell
39,036
-5,294
-12% -$311K 0.03% 321
2015
Q4 		$2.91M Sell
44,330
-23,083
-34% -$1.43M 0.31% 91
2015
Q3 		$3.81M Sell
67,413
-20,601
-23% -$1.34M 0.37% 72
2015
Q2 		$5.2M Buy
88,014
+4,591
+6% +$283K 0.46% 54
2015
Q1 		$5.2M Buy
83,423
+12,472
+18% +$725K 0.46% 55
2014
Q4 		$4.08M Buy
70,951
+11,617
+20% +$647K 0.35% 81
2014
Q3 		$3.19M Buy
59,334
+47,049
+383% +$2.49M 0.3% 86
2014
Q2 		$644K Sell
12,285
-336
-3% -$17.2K 0.06% 224
2014
Q1 		$667K Sell
12,621
-4,230
-25% -$196K 0.07% 217
2013
Q4 		$675K Sell
16,851
-4,145
-20% -$163K 0.07% 219
2013
Q3 		$793K Sell
20,996
-2,837
-12% -$111K 0.09% 184
2013
Q2 		$930K Buy
+23,833
New +$928K 0.11% 159

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RegentAtlantic Capital's TEVA Position: Q3 2022 in Review

RegentAtlantic Capital held its Teva Pharmaceuticals (TEVA) position steady in Q3 2022 at 10,205 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

RegentAtlantic Capital first reported a position in TEVA in Q2 2013 and has held it in 21 quarters since. The position peaked at $5.2M in Q2 2015. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • RegentAtlantic Capital held 10,205 shares of Teva Pharmaceuticals worth $82K as of Q3 2022.
  • RegentAtlantic Capital left its Teva Pharmaceuticals share count unchanged in Q3 2022.
  • Teva Pharmaceuticals made up ﹤0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #655 holding.
  • RegentAtlantic Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 21 quarters since.
  • RegentAtlantic Capital's Teva Pharmaceuticals position peaked at $5.2M in Q2 2015.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.